FrancophonIA/ELRC3.0 huggingface dataset:
English: For the 1.0 g/kg dose, similar volume adjustments can be made or alternate strengths can be used as shown in Table 2.
Slovenian: Za 1,0 g/kg odmerek lahko podobno prilagodite odmerek ali uporabite druge jakosti vial, kot je prikazano v preglednici 2.
English: - hepatitis B reactivation in HCV/HBV co-infected patients (recurrence of hepatitis B disease).
Slovenian: - reaktivacija hepatitisa B pri bolnikih, sočasno okuženih s HCV/HBV (ponovni pojav bolezni hepatitisa B).
English: In the treatment phase of this study, the most prevalent adverse reactions in all subjects were pyrexia (80 %), headache (62 %), neutropenia (33 %), fatigue (30 %), anorexia (29 %) and injection-site erythema (29 %).
Slovenian: V fazi zdravljenja te študije so bili neželeni učinki z največjo prevalenco pri vseh preiskovancih zvišana telesna temperatura (80 %), glavobol (62 %), nevtropenija (33 %), utrujenost (30 %), anoreksija (29 %) in eritem na mestu injiciranja (29 %).
English: Be sure the tip of needle is in the ViraferonPeg reconstituted solution.
Slovenian: Prepričajte se , da je vrh igle v rekonstituirani raztopini ViraferonPeg.
English: Bitherapy: Predictability of sustained virological response - All patients, irrespective of genotype, who have demonstrated serum HCV-RNA below the limits of detection at week 12 should receive 48 weeks of bitherapy.
Slovenian: Napoved trajnega virološkega odziva - Vsi bolniki ne glede na virusni genotip, ki so imeli v 12. tednu serumsko vrednost HCV-RNA pod mejo detekcije, morajo 48 tednov prejemati dvojno terapijo.
English: After withdrawal of the dose, any remaining solution must be discarded.
Slovenian: Po dajanju odmerka morate morebitno preostalo raztopino zavreči.
English: This medicine is used in combination with ribavirin in children 3 years of age and older and adolescents who have not been treated previously for chronic hepatitis C.
Slovenian: To zdravilo se uporablja v kombinaciji z ribavirinom pri otrocih, starih 3 leta ali več, in mladostnikih, ki se predhodno niso zdravili zaradi kroničnega hepatitisa C.
English: There were some cases of more severe neutropenia in patients treated with the recommended doses of ViraferonPeg in combination with ribavirin (WHO grade 3: 39 of 186 [21 %]; and WHO grade 4: 13 of 186 [7 %]).
Slovenian: Med bolniki, zdravljenimi s priporočenimi odmerki zdravila ViraferonPeg v kombinaciji z ribavirinom, je bilo nekaj primerov težje nevtropenije (3. stopnje po WHO: 39 od 182 [21 %] in 4. stopnje po WHO: 13 od 186 [7 %]).
English: For special handling information see section 6.6.
Slovenian: Za informacije glede ravnanja z zdravilom glejte poglavje 6.6.
English: Reduce only ViraferonPeg dose (see note 2) if:
Slovenian: Zmanjšajte le odmerek zdravila ViraferonPeg (glejte opombo 2) v primeru:
English: Midazolam (CYP3A4 substrate)
Slovenian: midazolam (substrat CYP3A4)
English:  2 g/dl decrease in haemoglobin during any four week period during treatment (permanent dose reduction)
Slovenian: Otroci in mladostniki: ne pride v poštev zmanjšanje vrednosti hemoglobina za  2 g/dl v katerem koli štiritedenskem obdobju med zdravljenjem (stalno zmanjšanje odmerka)
English: During combination therapy for up to 48 weeks with ViraferonPeg and ribavirin, growth inhibition was observed that resulted in reduced height in some patients (see section 4.4).
Slovenian: V času kombinirane terapije z zdravilom ViraferonPeg in ribavirinom, ki je trajala do 48 tednov, so opazili tudi zastoj rasti, ki je pri nekaterih bolnikih povzročil manjšo telesno višino (glejte poglavje 4.4).
English: Table 13 Sustained virological response based on genotype after ViraferonPeg in combination with Ribavirin in HCV/HIV Co-infected patients Study 1
Slovenian: Preglednica 13 Trajni virološki odziv glede na genotip po jemanju zdravila ViraferonPeg v kombinaciji z ribavirinom pri bolnikih, sočasno okuženih s HCV / HIV Študija 1
English: Females of childbearing potential must use an effective contraceptive during treatment and for 4 months after treatment has been concluded.
Slovenian: Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo med zdravljenjem in še 4 mesece po zaključku zdravljenja.
English: Non-responders to prior therapy with pegylated interferon alpha/ribavirin were less likely to achieve a week 12 response to retreatment than non-responders to nonpegylated interferon alpha/ribavirin (12.4 % vs. 28.6 %).
Slovenian: Pri bolnikih, ki se niso odzvali na predhodno zdravljenje s pegiliranim interferonom alfa/ribavirinom, je bila verjetnost, da se bodo odzvali na ponovno zdravljenje v 12. tednu, manjša kot pri tistih, ki se niso odzvali na zdravljenje z nepegiliranim interferonom alfa/ribavirinom (12,4 % vs. 28,6 %).
English: - are infected with both Human Immunodeficiency Virus (HIV-positive) and Hepatitis C Virus (HCV) and are being treated with an anti-HIV medicine(s) - [nucleoside reverse transcriptase inhibitor (NRTI), and/or highly active anti-retroviral therapy (HAART)].
Slovenian: - ste sočasno okuženi z virusom humane imunske pomanjkljivosti (HIV- pozitivni) in z virusom hepatitisa C (HCV) in se zdravite z zdravili proti virusu HIV - [z nukleozidnimi zaviralci reverzne transkriptaze (NRTI) in/ali visoko aktivno protiretrovirusno terapijo (HAART)].
English: Response week 12 was defined as undetectable HCVRNA after 12 weeks of treatment.
Slovenian: Odziv v 12. tednu so opredelili kot nemerljivo HCV-RNA po 12 tednih zdravljenja.
English: Figure 10: Thigh injection
Slovenian: Slika 10: Injiciranje v stegno
English: ViraferonPeg showed no genotoxic potential.
Slovenian: Zdravilo ViraferonPeg ni pokazalo nikakršne genotoksičnosti.
English: Any patient developing pyrexia, cough, dyspnea or other respiratory symptoms must have a chest X-ray taken.
Slovenian: Pri vsakem bolniku, pri katerem se pojavijo zvišana telesna temperatura, kašelj, dispnea ali drugi respiratorni simptomi, je treba opraviti rentgensko slikanje prsnega koša.
English: * Any subject with an undetectable HCV-RNA level at the follow-up week 12 visit and missing data at the follow-up week 24 visit was considered a sustained responder.
Slovenian: * Vsakega preiskovanca z nemerljivo koncentracijo HCV-RNA ob obisku v 12. tednu spremljanja in z manjkajočimi podatki ob obisku v 24. tednu spremljanja so šteli med bolnike s trajnim virološkim odzivom.
English: Bacterial infection (including sepsis), fungal infection, influenza, upper respiratory tract infection, bronchitis, herpes simplex, sinusitis, otitis media, rhinitis
Slovenian: bakterijska okužba (vključno s sepso), glivična okužba, gripa, okužba zgornjih dihal, bronhitis, herpes simpleks, sinusitis, otitis media, rinitis
English: HCV infected patients having a co-occurring substance use disorder (alcohol, cannabis, etc) are at an increased risk of developing psychiatric disorders or exacerbation of already existing psychiatric disorders when treated with alpha interferon.
Slovenian: Pri bolnikih, okuženih s HCV, ki sočasno uživajo tudi opojne substance (alkohol, marihuano itd.), je med zdravljenjem z interferonom alfa povečano tveganje za pojav psihiatričnih motenj ali za poslabšanje že obstoječih psihiatričnih motenj.
English: At the ViraferonPeg 1.5 µg/kg plus ribavirin dose, sustained virologic response rates were lower in patients with cirrhosis, in patients with normal ALT levels, in patients with a baseline viral load > 600,000 IU/ml, and in patients > 40 years old.
Slovenian: Pri odmerku zdravila ViraferonPeg 1,5 µg/kg z ribavirinom so bili deleži trajnega virološkega odziva nižji pri bolnikih s cirozo, pri bolnikih z normalnimi vrednostmi ALT, pri bolnikih z začetnim virusnim bremenom > 600.000 i.e./ml in pri bolnikih > 40 let.
English: A small volume is lost during preparation of this medicine for injection and when the dose is measured and injected.
Slovenian: Manjša količina zdravila se izgubi med pripravo tega zdravila za injiciranje, ko odmerjamo odmerek in ga injiciramo.
English: In a single dose study (1.0 microgram/kg) in patients with impaired renal function, Cmax, AUC, and half-life increased in relation to the degree of renal impairment.
Slovenian: V študiji enkratnega odmerka zdravila (1,0 mikrogram/kg) pri bolnikih z ledvično okvaro so vrednosti Cmax, AUC in razpolovne dobe naraščale glede na stopnjo ledvične okvare.
English: Tolbutamide (CYP2C9 substrate)
Slovenian: tolbutamid (substrat CYP2C9)
English: ViraferonPeg pre-filled pen is to be removed from the refrigerator before administration to allow the solvent to reach room temperature (not more than 25°C).
Slovenian: Pred uporabo vzemite napolnjeni injekcijski peresnik ViraferonPeg iz hladilnika, da se bo vehikel ogrel na sobno temperaturo (ne več kot 25C).
English: Eligible patients for these trials had chronic hepatitis C confirmed by a positive HCV-RNA polymerase chain reaction (PCR) assay (> 30 IU/ml), a liver biopsy consistent with a histological diagnosis of chronic hepatitis with no other cause for the chronic hepatitis, and abnormal serum ALT.
Slovenian: V ti raziskavi so vključili bolnike s kroničnim hepatitisom C, potrjenim s pozitivno verižno reakcijo s polimerazo (PCR test) na HCV-RNA (> 30 i.e./ml), izvidom jetrne biopsije v skladu s histološko diagnozo kroničnega hepatitisa brez drugih ugotovljenih vzrokov za to bolezen in z nenormalnimi vrednostmi serumske ALT.
English: Female: Dysmenorrhoea
Slovenian: ženske: dismenoreja
English: ViraferonPeg is a well characterized polyethylene glycol-modified (“pegylated”) derivative of interferon alfa-2b and is predominantly composed of monopegylated species.
Slovenian: Zdravilo ViraferonPeg je dobro opredeljen derivat interferona alfa-2b, modificiran s polietilenglikolom ("pegiliran"), in je sestavljen pretežno iz monopegiliranih vrst.
English: Contusion class effect of interferon-alfa containing products - reported with standard interferon therapy in adult and paediatric patients; with ViraferonPeg reported in adult patients.
Slovenian: Učinek, značilen za skupino zdravil, ki vsebujejo interferon-alfa - pri standardnem interferonskem zdravljenju so o njem poročali pri odraslih in pediatričnih bolnikih; pri zdravljenju z zdravilom ViraferonPeg so o njem poročali pri odraslih bolnikih.
English: If you forget to take ViraferonPeg
Slovenian: Če ste pozabili vzeti zdravilo ViraferonPeg
English: - Remove the needle guard without touching the needle and keep the syringe with the needle in your hand.
Slovenian: - Z igle odstranite zaščitni pokrovček, ne da bi se dotaknili igle, in brizgo z iglo obdržite v roki.
English: In a clinical trial, approximately 1.2 % of patients treated with ViraferonPeg or interferon alfa-2b in combination with ribavirin reported life-threatening psychiatric events during treatment.
Slovenian: V kliničnem preskušanju so pri približno 1,2 % bolnikov, zdravljenih z zdravilom ViraferonPeg ali z interferonom alfa-2b v kombinaciji z ribavirinom med zdravljenjem poročali o smrtno nevarnih duševnih motnjah.
English: Cardiovascular (CVS) adverse events, particularly arrhythmia, appeared to be correlated mostly with pre-existing CVS disease and prior therapy with cardiotoxic agents (see section 4.4).
Slovenian: Videti je bilo, da so bili kardiovaskularni (KVS) neželeni učinki, še posebej aritmija, povezani predvsem z obstoječo KVS boleznijo in predhodno terapijo s kardiotoksičnimi snovmi (glejte poglavje 4.4).
English: Retreated patients who fail to achieve virological response (i.e. HCV-RNA below the limits of detection) at week 12 are unlikely to become sustained virological responders after 48 weeks of therapy (see also section 5.1).
Slovenian: Pri ponovno zdravljenih bolnikih, ki v 12. tednu niso imeli virološkega odziva (tj. vrednost HCV-RNA pod mejo detekcije), pa je malo verjetno, da bodo po 48 tednih zdravljenja dosegli trajen virološki odziv (glejte tudi poglavje 5.1).
English: • Wipe the top of the pre-filled pen where the needle is going to be attached with an alcohol swab (see Figure 4).
Slovenian: • Vrhnji del napolnjenega injekcijskega peresnika, kamor pride igla, obrišite z alkoholnim tamponom (glejte sliko 4).
English: However, certain monkey species, e.g., Rhesus monkeys are susceptible to pharmacodynamic stimulation upon exposure to human type 1 interferons.
Slovenian: Študije z drugimi interferoni so pokazale vrstno specifičnost, vendar pa so nekatere vrste opic, npr. Rhesus opice, občutljive na farmakodinamično stimulacijo s človeškimi interferoni tipa 1.
English: Dose modification for all patients (monotherapy and combination therapy) If severe adverse reactions or laboratory abnormalities develop during treatment with ViraferonPeg monotherapy or combination therapy, the dosages of ViraferonPeg and/or ribavirin must be modified as appropriate, until the adverse reactions abate.
Slovenian: Prilagajanje odmerka pri vseh bolnikih (monoterapija in kombinirana terapija) Če se med zdravljenjem z zdravilom ViraferonPeg v monoterapiji ali v kombinirani terapiji pojavijo resni neželeni učinki ali nenormalni laboratorijski izvidi, morate ustrezno prilagoditi odmerke zdravila ViraferonPeg in/ali ribavirina, dokler neželeni učinki ne prenehajo.
English: For HCV/HIV co-infected patients receiving ViraferonPeg in combination with ribavirin, other undesirable effects (that were not reported in mono-infected patients) which have been reported in the larger studies with a frequency > 5 % were: oral candidiasis (14 %), lipodystrophy acquired (13 %), CD4 lymphocytes decreased (8 %), appetite decreased (8 %), gamma-glutamyltransferase increased (9 %), back pain (5 %), blood amylase increased (6 %), blood lactic acid increased (5 %), cytolytic hepatitis (6 %), lipase increased (6 %) and pain in limb (6 %).
Slovenian: Pri bolnikih, ki so bili sočasno okuženi s HCV/HIV in so prejemali zdravilo ViraferonPeg v kombinaciji z ribavirinom, so drugi neželeni učinki (o katerih niso poročali pri bolnikih s samo eno okužbo), o katerih so poročali v večjih študijah s pogostnostjo > 5 %, bili: oralna kandidiaza (14 %), pridobljena lipodistrofija (13 %), zmanjšano število limfocitov CD4 (8 %), zmanjšan apetit (8 %), zvišana vrednost gama glutamiltransferaze (9 %), bolečine v hrbtu (5 %), zvišana vrednost amilaze v krvi (6 %), zvišana koncentracija mlečne kisline v krvi (5 %), citolitični hepatitis (6 %), zvišana vrednost lipaze (6 %) in bolečine v udih (6 %).
English: Clinical efficacy and safety - Adults Tritherapy with ViraferonPeg, ribavirin and boceprevir Refer to the SmPC for boceprevir.
Slovenian: Klinična učinkovitost in varnost - odrasli Trojna terapija z zdravilom ViraferonPeg, ribavirinom in boceprevirjem: glejte SmPC za boceprevir.
English: Reminder to adult patients prescribed combination therapy of this medicine, boceprevir and ribavirin: Please read the “Possible side effects” section of these Package Leaflets.
Slovenian: Opozorilo za odrasle bolnike, ki imajo predpisano zdravljenje s tem zdravilom, boceprevirjem in ribavirinom: Prosimo, preberite poglavje "Možni neželeni učinki" v teh navodilih za uporabo.
English: Dextromethorphan hydrobromide (CYP2D6 and CYP3A substrate)
Slovenian: dekstrometorfanijev bromid (substrat CYP2D6 in CYP3A)
English: Serum Creatinine
Slovenian: Serumski kreatinin
English: By week 12 (n= 215) HCV-RNA negative or ≥ 2 log decrease in viral load
Slovenian: Do 12. tedna (n= 215) Negativna HCV-RNA ali zmanjšanje virusnega bremena za ≥ 2 log
English: Other CNS effects including aggressive behaviour (sometimes directed against others such as homicidal ideation), bipolar disorders, mania, confusion and alterations of mental status have been observed with alpha interferons.
Slovenian: Pri interferonih alfa so opažali tudi druge učinke na CŽS, vključno z agresivnostjo (ki je včasih usmerjena proti drugim kot je ideja o umoru), bipolarno motnjo, manijo, zmedenostjo in spremembami duševnega stanja.
English: A large long-term follow-up study enrolled 567 patients after treatment in a prior study with ViraferonPeg (with or without ribavirin).
Slovenian: Podatki o dolgoročni učinkovitosti zdravila - odrasli V veliko dolgoročno študijo spremljanja bolnikov je bilo vključenih 567 bolnikov, ki so zaključili zdravljenje z zdravilom ViraferonPeg (z ali brez ribavirina) v okviru prejšnje študije.
English: Hepatic decompensation in HCV/HIV co-infected patients with advanced cirrhosis Co-infected patients with advanced cirrhosis receiving HAART may be at increased risk of hepatic decompensation and death.
Slovenian: Jetrna dekompenzacija pri s HCV/HIV sočasno okuženih bolnikih z napredovalo cirozo jeter Sočasno okuženi bolniki z napredovalo cirozo jeter, ki prejemajo HAART, imajo lahko večje tveganje za jetrno dekompenzacijo in smrt.
English: Talk to your doctor before taking this medicine if you, or the child you are caring for: - have had a severe nervous or mental disorder or have a history of substance abuse (e.g. alcohol or drugs).
Slovenian: Pred začetkom uporabe tega zdravila se posvetujte z zdravnikom, če za vas ali vašega otroka velja kaj od naštetega: - ste kdaj v preteklosti imeli hudo bolezen živčevja ali duševno bolezen ali ste v preteklosti zlorabljali opojne substance (npr. alkohol ali droge).
English: ViraferonPeg should be used with caution in patients with moderate to severe renal impairment.
Slovenian: Zdravilo ViraferonPeg morate uporabljati previdno pri bolnikih z zmerno do hudo ledvično okvaro.
English: Very rarely, seizures have occurred with high doses of interferon alpha.
Slovenian: Zelo redko so se pri velikih odmerkih interferona alfa pojavili epileptični napadi.
English: Please refer to the respective SmPCs of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with ViraferonPeg and ribavirin.
Slovenian: Prosimo, glejte ustrezne SmPC-je za antiretrovirusna zdravila, ki jih bo bolnik jemal skupaj s terapijo za HCV, za informacije o toksičnih učinkih in ustreznem ukrepanju za vsako zdravilo ter za informacije o potencialnem prekrivanju njihovih toksičnih učinkov z zdravilom ViraferonPeg in ribavirinom.
English: How to store ViraferonPeg Contents of the pack and other information
Slovenian: Shranjevanje zdravila ViraferonPeg Vsebina pakiranja in dodatne informacije
English: Adults (tritherapy)
Slovenian: Odrasli (trojna terapija)
English: Hepatitis B reactivation in HCV/HBV co-infected patients Blood and lymphatic system disorders Very common:
Slovenian: reaktivacija hepatitisa B pri bolnikih, sočasno okuženih s HCV/HBV Bolezni krvi in limfatičnega sistema Zelo pogosti:
English: Data from elderly patients treated with a single dose of ViraferonPeg suggest no alteration in ViraferonPeg dose is necessary based on age (see section 5.2).
Slovenian: Podatki, dobljeni pri starejših bolnikih, ki so jih zdravili z enkratnim odmerkom zdravila ViraferonPeg, kažejo, da zaradi starosti ni potrebna sprememba odmerka zdravila ViraferonPeg (glejte poglavje 5.2).
English: The response to treatment in both of these trials is presented in Table 13.
Slovenian: V preglednici 13 je predstavljen odziv bolnikov na zdravljenje v obeh preskušanjih.
English: Paediatric population (bitherapy only) - Dose to be administered Dosing for children 3 years of age and older and adolescent patients is determined by body surface area for ViraferonPeg and by body weight for ribavirin.
Slovenian: Pediatrična populacija (samo dvojna terapija) - odmerek za injiciranje Odmerek za otroke, stare 3 leta in več, in mladostnike za zdravilo ViraferonPeg se določi glede na bolnikovo telesno površino, za ribavirin pa glede na bolnikovo telesno maso.
English: The active substance in this medicine is a protein called peginterferon alfa-2b, which belongs to the class of medicines called interferons.
Slovenian: Učinkovina v tem zdravilu je protein peginterferon alfa-2b, ki spada v skupino zdravil, ki jih imenujemo interferoni.
English: Children and adolescents should be monitored every 3 months for evidence of thyroid dysfunction (e.g. TSH).
Slovenian: Otroke in mladostnike je treba spremljati na vsake 3 mesece in pri njih iskati morebitne motnje delovanja ščitnice (npr. spremembe vrednosti TSH).
English: The major treatment-related change was a reversible, mild to moderate anaemia, the severity of which was greater than that produced by either active substance alone.
Slovenian: Največja razlika v zdravljenju je bila reverzibilna, blaga do zmerna anemija, ki je bila hujša kot pri ločeni uporabi vsake od teh dveh učinkovin.
English: • Support the pre-filled pen in upright position and push the needle straight down firmly (see Figure 6).
Slovenian: • Napolnjeni injekcijski peresnik držite pokonci in iglo čvrsto potisnite naravnost navzdol (glejte sliko 6).
English: Remove the needle guard from the syringe needle and check for air bubbles in the syringe.
Slovenian: Snemite zaščitni pokrovček z igle na brizgi in preverite, ali so v brizgi zračni mehurčki.
English: - Do not shake, but gently turn the vial upside down until any powder at the top of the vial is dissolved.
Slovenian: Ne stresajte, ampak nežno obračajte vialo narobe, da se bo popolnoma raztopil tudi prašek na vrhu viale.
English: Measuring the dose of ViraferonPeg from the reconstituted powder for injection Turn the vial and the syringe upside down in one hand.
Slovenian: Merjenje odmerka zdravila ViraferonPeg iz rekonstituiranega praška za injekcije Vialo in brizgo držite obrnjeno narobe v eni roki.
English: Adverse events not observed in clinical trials were not seen in toxicity studies in monkeys.
Slovenian: V toksikoloških študijah na opicah niso opažali nobenih neželenih učinkov, ki jih ne bi opazili že v kliničnih preskušanjih.
English: Dispose of the used pre-filled pen safely in a closed container.
Slovenian: Uporabljeni napolnjeni injekcijski peresnik varno zavrzite v zaprt vsebnik.
English: a: 2 morning, 2 evening b: 2 morning, 3 evening c: 3 morning, 3 evening d: 3 morning, 4 evening * Refer to the SmPC of boceprevir for details about the dose of boceprevir to be administered in tritherapy.
Slovenian: a: 2 zjutraj, 2 zvečer b: 2 zjutraj, 3 zvečer c: 3 zjutraj, 3 zvečer d: 3 zjutraj, 4 zvečer
English: Myalgia, arthralgia
Slovenian: mialgija, artralgija
English: The cartridge is sealed at one end with a polypropylene cap containing a bromobutyl rubber liner and at the other end by a bromobutyl rubber plunger.
Slovenian: Vložek je na enem koncu zaprt s polipropilenskim pokrovčkom s prevleko iz bromobutilne gume in na drugem z batom iz bromobutilne gume.
English: Healthy Subjects (N=24)
Slovenian: zdravi preiskovanci (n = 24)
English: • Genotype 1: - Patients who have undetectable HCV-RNA at treatment week 12, treatment should be continued for another nine month period (i.e., a total of 48 weeks).
Slovenian: • Genotip 1: - Bolniki, ki imajo nemerljivo koncentracijo HCV-RNA v 12. tednu zdravljenja, naj nadaljujejo z zdravljenjem še eno 9-mesečno obdobje (tj. skupaj 48 tednov).
English: Pulmonary changes
Slovenian: Spremembe na pljučih
English: Metabolism of other medicines in the liver may be suppressed.
Slovenian: Presnova drugih zdravil v jetrih se lahko upočasni.
English: Combination therapy dose reduction guidelines
Slovenian: Smernice za zmanjšanje odmerka pri kombinirani terapiji
English: NR: Non-responder defined as serum/plasma HCV-RNA positive at the end of a minimum of 12 weeks of treatment.
Slovenian: NR: Neodzivni bolniki so opredeljeni kot tisti, ki imajo pozitiven izvid serumske/plazemske HCV-RNA ob koncu najmanj 12 tednov zdravljenja.
English: Haematological abnormalities were more frequently reported in patients receiving ViraferonPeg in combination with ribavirin when compared to patients receiving interferon alfa-2b in combination with ribavirin.
Slovenian: O nenormalnih hematoloških izvidih so poročali pogosteje pri bolnikih, ki so prejemali zdravilo ViraferonPeg v kombinaciji z ribavirinom, kot pri tistih, ki so prejemali interferon alfa-2b v kombinaciji z ribavirinom.
English: Do not inject into this site; withdraw the needle and repeat the procedure.
Slovenian: Izvlecite iglo in ponovite postopek.
English: - are being treated with telbivudine (see section “Other medicines and ViraferonPeg”).
Slovenian: - če se zdravite s telbivudinom (glejte poglavje "Druga zdravila in zdravilo ViraferonPeg").